CClinicalTrials.gg
CompletedNCT07528573Updated Apr 14, 2026

HIV Prevention and Care Engagement in Nepal

An interventional study of Sweekar intervention in HIV, sponsored by Public Health Foundation Enterprises, Inc.. Completed at 1 site in Nepal. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Public Health Foundation Enterprises, Inc. · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled May 2024, registered Oct 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This intervention focuses on increasing HIV testing, HIV medication adherence and reducing intersectional stigma. Our Sweekar intervention will implement 5 months of group-based activities to address the social stigma and HIV prevention and care needs.

02

Conditions studied

  • HIV
03

In context

Lead sponsor

Public Health Foundation Enterprises, Inc. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  1. aged 18 years old or older
  2. identify as transgender, hijra, Meti, third gender or anything other than a gender typically associated with a male assigned sex at birth
  3. live in the Terai highway district Madesh Province
  4. Maithili- or Nepali-speaking
  5. Willing to be part of the study for 6 months
  6. Willing to travel, if needed, to participate in group sessions

For those who test HIV negative:

  1. Willing to self-test
  2. Have or willing to have a mobile phone
  3. Not HIV tested within the last 3 months

For those who test HIV positive:

(a) screen positive for HIV treatment non-adherence by self-report

Exclusion criteria

Exclusion Criteria:

  1. Cannot or will not consent to the research,
  2. Female sex assigned at birth,
  3. Self-identify as a man
  4. Do not speak Maithli or Nepali
  5. Age under 18 -
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Group-based intervention

    Group-based activities and HIV self-testing to address social stigma and HIV prevention and care needs

    Behavioral: Sweekar intervention

Interventions

  • BehavioralSweekar intervention

    The HIV prevention components focus on HIV education and use of HIV self-testing kits to increase frequency of HIV testing. The HIV care component is information and linkage to HIV treatment information and adherence support.

06

What researchers measure

Primary outcomes

  1. HIV testing Self-testing kits

    Number of HIV self tests kits used at home or at a hospital or clinic

    Time frame: At baseline and at 3 months

  2. HIV testing frequency

    HIV testing; Number of times received HIV testing using clinic or resources that is not HIV self-testing kits

    Time frame: Baseline, 3 months and 6 months

  3. HIV treatment engagement

    Self-reported Wilson's Medication Scale to assess adherence patterns.

    Time frame: At baseline, 3 months and 6 months

07

Study locations

1 site
  • BDS
    Kathmandu, Nepal
08

References and documents

Individual participant data

Plan to share: Undecided — Upon request, data may be made available

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07528573
Lead sponsor
Public Health Foundation Enterprises, Inc.
Collaborators
Fogarty International Center of the National Institute of Health
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
May 27, 2024
Primary completion
May 31, 2025
Completion
May 31, 2025
Last update
Apr 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion